Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

163 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Auguste A, Genestie C, De Bruyn M, Adam J, Le Formal A, Drusch F, Pautier P, Crosbie EJ, MacKay H, Kitchener HC, Powell M, Pollock PM, Mileshkin L, Edmondson RJ, Nout R, Nijman HW, Creutzberg CL, Bosse T, Leary A. Auguste A, et al. Among authors: genestie c. Mod Pathol. 2018 Dec;31(12):1851-1861. doi: 10.1038/s41379-018-0055-1. Epub 2018 Jun 28. Mod Pathol. 2018. PMID: 29955143 Free article.
Clinical transfer of AGuIX®-based radiation treatments for locally advanced cervical cancer: MR quantification and in vitro insights in the NANOCOL clinical trial framework.
Maury P, Mondini M, Chargari C, Darricau A, Shahin M, Ammari S, Bockel S, Genestie C, Wu TD, Lux F, Tillement O, Lacombe S, Deutsch E, Robert C, Porcel E. Maury P, et al. Among authors: genestie c. Nanomedicine. 2023 Jun;50:102676. doi: 10.1016/j.nano.2023.102676. Epub 2023 Apr 20. Nanomedicine. 2023. PMID: 37084803
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor.
Ducarouge B, Redavid AR, Victoor C, Chira R, Fonseca A, Hervieu M, Bergé R, Lengrand J, Vieugué P, Neves D, Goddard I, Richaud M, Laval PA, Rama N, Goldschneider D, Paradisi A, Gourdin N, Chabaud S, Treilleux I, Gadot N, Ray-Coquard I, Depil S, Decaudin D, Némati F, Marangoni E, Mery-Lamarche E, Génestie C, Tabone-Eglinger S, Devouassoux-Shisheboran M, Moore KJ, Gibert B, Mehlen P, Bernet A. Ducarouge B, et al. Among authors: genestie c. Cell Death Differ. 2023 Oct;30(10):2201-2212. doi: 10.1038/s41418-023-01209-x. Epub 2023 Aug 26. Cell Death Differ. 2023. PMID: 37633969 Free PMC article.
[Application in France of the 2021 European recommendations on endometrial cancer].
Deluche E, Marti C, Jochum F, Bendifallah S, Azaïs H, Deidier J, Cockenpot V, Menoux I, Kissel M, Balaya V, Betrian S, Mathevet P, Chargari C, Gouy S, Genestie C, Uzan C, Devouassoux-Shisheboran M, Guyon F, Akladios C, Body N, Guani B; groupe SFOG et SFOG campus. Deluche E, et al. Among authors: genestie c. Bull Cancer. 2023 Jan;110(1):55-68. doi: 10.1016/j.bulcan.2022.11.003. Epub 2022 Nov 30. Bull Cancer. 2023. PMID: 36462971 Review. French.
Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P, Genestie C, Fizazi K, Morice P, Mottet C, Haie-Meder C, Le Cesne A, Lhommé C. Pautier P, et al. Among authors: genestie c. Int J Gynecol Cancer. 2002 Nov-Dec;12(6):749-54. doi: 10.1046/j.1525-1438.2002.01144.x. Int J Gynecol Cancer. 2002. PMID: 12445254
163 results